| # |
Company Name
|
Industry Name
|
Latest Price (Rs.)
|
Price Change
Rs (%) |
Market Cap
|
Net Sales
(Rs. Cr.) |
Latest EPS
(Rs.) |
Net Profit
Margin % |
Latest
P/E |
Latest
P/BV |
|---|---|---|---|---|---|---|---|---|---|---|
| Dr. Reddys Labs. | Pharmaceuticals& Drugs | 1,175 |
-11.4 (-0.96%) |
Mid Cap | 33,700 | 38.6 | 11.44 | 30.4 | 2.6 | |
| Cipla | Pharmaceuticals& Drugs | 1,419.9 |
11.5 (0.82%) |
Mid Cap | 28,163 | 41.7 | 13.45 | 34 | 3.3 | |
| Lupin | Pharmaceuticals& Drugs | 2,164.6 |
-26.6 (-1.21%) |
Mid Cap | 27,958 | 120.9 | 18.82 | 17.9 | 4.2 | |
| Zydus Lifesciences | Pharmaceuticals& Drugs | 1,189 |
41.05 (3.58%) |
Mid Cap | 27,148 | 45.2 | 16.54 | 26.3 | 4.4 | |
| Glenmark Pharma. | Pharmaceuticals& Drugs | 2,456 |
16 (0.66%) |
Mid Cap | 16,983 | 63.7 | 15.9 | 38.6 | 6.3 | |
| Aurobindo Pharma | Pharmaceuticals& Drugs | 1,631 |
9 (0.55%) |
Mid Cap | 11,172 | 45.1 | 20.59 | 36.2 | 4 | |
| Mankind Pharma | Pharmaceuticals& Drugs | 2,417 |
24 (1%) |
Mid Cap | 10,421 | 52.8 | 19.97 | 45.8 | 5.9 | |
| Alkem Laboratories | Pharmaceuticals& Drugs | 5,314.4 |
-25.85 (-0.48%) |
Mid Cap | 9,664 | 178.4 | 22.7 | 29.8 | 4.4 | |
| Ipca Laboratories | Pharmaceuticals& Drugs | 1,958.7 |
6.75 (0.35%) |
Mid Cap | 7,289 | 49 | 16.38 | 40 | 6 | |
| Abbott India | Pharmaceuticals& Drugs | 26,378.4 |
-122.75 (-0.46%) |
Mid Cap | 6,929 | 759.9 | 22.25 | 34.7 | 10.8 | |
| Laurus Labs | Pharmaceuticals& Drugs | 1,920 |
32 (1.69%) |
Mid Cap | 6,813 | 20.2 | 12.82 | 94.9 | 18.4 | |
| Ajanta Pharma | Pharmaceuticals& Drugs | 3,540.7 |
-4.45 (-0.13%) |
Mid Cap | 5,453 | 90.8 | 19.33 | 39 | 9.1 | |
| Glaxosmithkline Phar | Pharmaceuticals& Drugs | 3,068.4 |
40.85 (1.35%) |
Mid Cap | 3,822 | 63.1 | 25.36 | 48.7 | 20.6 | |
| Biocon | Pharmaceuticals& Drugs | 417.8 |
0.4 (0.1%) |
Mid Cap | 2,346 | 0.6 | 5.85 | 696.9 | 2.5 | |
| Anthem Biosciences | Pharmaceuticals& Drugs | 924.1 |
0.6 (0.06%) |
Mid Cap | 2,089 | 11.1 | 30.95 | 83.4 | 16 |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: